Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

11.42 -0.66 (-5.46%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS

May 05, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting

April 02, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings For Amylyx Pharmaceuticals ↗

April 01, 2022

Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:

Via Benzinga

FDA Panel Votes Down For Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success ↗

March 31, 2022

An advisory committee of the

Via Benzinga

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest ↗

April 01, 2022

One analyst says Reata only has a 50% chance in a neurodegenerative disease.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022 ↗

April 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗

March 31, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Amylyx Pharma Stock Hinges On This FDA Action — Here's What To Know ↗

March 30, 2022

Amylyx is facing an FDA advisory committee Wednesday that will vote on its ALS drug.

Via Investor's Business Daily

Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug ↗

March 28, 2022

Via Benzinga

Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Amylyx Pharmaceuticals Stock Trading Halted Today

March 30, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

50 Biggest Movers From Yesterday ↗

March 29, 2022

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in...

Via Benzinga

Mid-Day Market Update: Crude Oil Dips 8%; Plantronics Shares Spike Higher ↗

March 28, 2022

U.S. stocks traded mixed midway through trading, with the Dow dropping 175 points on Monday.

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

March 28, 2022

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron....

Via Benzinga

Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment ↗

March 28, 2022

Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.

Via Investor's Business Daily

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035

March 28, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

March 28, 2022

On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Mid-Morning Market Update: Markets Mixed; SAIC Profit Tops Views ↗

March 28, 2022

U.S. stocks traded mixed this morning, with the Dow dropping around 100 points on Monday.

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO ↗

March 26, 2022

Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...

Via Talk Markets

IPO Stock Amylyx Pharmaceuticals Broke Down — But Just Wait For Its Encore ↗

March 25, 2022

Here's why a former breakdown stock, Amylyx, has run up for two consecutive days.

Via Investor's Business Daily

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

March 18, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

7 Biotech Stocks With Key Catalysts in March ↗

March 09, 2022

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

Via InvestorPlace

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗

March 02, 2022

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...

Via Benzinga

80 Biggest Movers From Yesterday ↗

March 02, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...

Via Benzinga

Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS

February 25, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel

February 23, 2022

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.